- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05147350
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (MINOTAUR)
March 8, 2024 updated by: Repare Therapeutics
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
To assess the safety and tolerability of RP-6306 in combination with FOLFIRI in patients with eligible, advanced solid tumors.
Incidence and severity of treatment-emergent adverse events (TEAEs), laboratory assessments, vital signs, electrocardiograms (ECGs), and use of concomitant medications.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nathan Hawkey, MD, MBA
- Phone Number: +1 857-340-5416
- Email: clininfo@reparerx.com
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, ON M5G 2M9
- Participating site # 2001
-
-
-
-
-
Madrid, Spain
- Site 5002
-
Madrid, Spain
- Site 5003
-
-
-
-
-
London, United Kingdom, W1G 6AD
- Participating Site # 3003
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Participating site #1019
-
-
Florida
-
Tampa, Florida, United States, 33612
- Site 1022
-
-
New York
-
New York, New York, United States, 10032
- Participating Site #1008
-
-
Texas
-
Houston, Texas, United States, 77030
- Participating Site #1001
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Participating Site #1013
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female and ≥18 years-of-age at the time of signature of the informed consent
- Confirmed advanced solid tumors resistant or refractory to standard treatment
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- All patients must have locally advanced or metastatic CRC, GI, or esophageal cancer(s) and radiographic evidence of progressing disease.
- Measurable disease as per RECIST v1.1
- Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible
- Acceptable hematologic and organ function at screening
- Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug.
Exclusion Criteria:
- Inability to swallow and retain oral medications.
- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half- lives, whichever is shorter, prior to first dose of study treatment.
- History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
- Patients who are pregnant or breastfeeding
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
- Major surgery within 4 weeks prior to first study treatment dose.
- Uncontrolled, symptomatic brain metastases.
- Uncontrolled high blood pressure
- Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
- Moderate or severe hepatic impairment
- Cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥Class 2
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation
RP-6306 will be administered as oral capsules Multiple dose levels of RP-6306 (oral) and FOLFIRI (IV)
|
RP-6306 (Oral) in combination with FOLFIRI (IV)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with of treatment-related adverse event data per CTCAE v5.0 criteria and frequency of dose limiting toxicities, to determine safety and tolerability of RP-6306 in combination with FOLFIRI.
Time Frame: Up to 90 days after last administration of study intervention
|
This data will be used to identify a recommended phase 2 dose (RP2D) and schedule of RP-6306 in combination with FOLFIRI
|
Up to 90 days after last administration of study intervention
|
To identify a maximum tolerated dose (MTD)
Time Frame: Up to 90 days after last administration of study intervention
|
through evaluation of dose-limiting toxicities (DLTs) at or below a frequency of 25%.
|
Up to 90 days after last administration of study intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration versus time curve (AUC) from time 0 to 8 hours post dose
Time Frame: Through end of study, up to 2 months
|
PK parameters of RP-6306, irinotecan, and SN-38
|
Through end of study, up to 2 months
|
Peak Plasma Concentration (Cmax) will be observed directly from data
Time Frame: Through end of study, up to 2 months
|
PK parameters of RP-6306, irinotecan, and SN-38
|
Through end of study, up to 2 months
|
Minimum blood plasma concentration (Cmin) will be observed directly from data
Time Frame: Through end of study, up to 2 months
|
PK parameters of RP-6306, irinotecan, and SN-38
|
Through end of study, up to 2 months
|
Time take to reach Cmax (Tmax) will be observed directly from data as time of first occurrence
Time Frame: Through end of study, up to 2 months
|
PK parameters of RP-6306, irinotecan, and SN-38
|
Through end of study, up to 2 months
|
Best percent change in tumor size from baseline
Time Frame: objective response rate, best overall response rate, duration of response, clinical benefit rate, progression-free survival at 6 months, and overall survival at 12 months
|
To assess the preliminary efficacy of RP 6306 in combination with FOLFIRI in patients with molecularly selected, advanced solid tumors
|
objective response rate, best overall response rate, duration of response, clinical benefit rate, progression-free survival at 6 months, and overall survival at 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Nathan Hawkey, Repare RX
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 9, 2022
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
November 1, 2026
Study Registration Dates
First Submitted
November 3, 2021
First Submitted That Met QC Criteria
December 6, 2021
First Posted (Actual)
December 7, 2021
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 8, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-6306-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
GI Innovation, Inc.RecruitingAdvanced Solid Tumor | Metastatic Solid TumorKorea, Republic of, United States
-
Xenthera, Inc.Not yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on RP-6306 (oral PKMYT1 inhibitor)
-
Repare TherapeuticsActive, not recruitingAdult Solid TumorUnited States, Canada, United Kingdom
-
Repare TherapeuticsDebiopharm International SARecruitingAdvanced Solid TumorUnited States, Canada, Denmark
-
PfizerCompleted
-
University Health Network, TorontoActive, not recruitingMetastatic Cancer | Advanced Cancer | Recurrent Ovarian Cancer | Recurrent Uterine CancerCanada
-
Canadian Cancer Trials GroupRepare TherapeuticsRecruiting
-
Mayo ClinicNational Center for Advancing Translational Sciences (NCATS)Completed
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
PfizerTerminatedAnkylosing SpondylitisUnited States, Canada
-
Array Biopharma, now a wholly owned subsidiary...CompletedRheumatoid ArthritisBrazil, Argentina, United States, Poland, Hungary, Peru, Romania
-
Array Biopharma, now a wholly owned subsidiary...Completed